Better diabetes care for people with physical disabilities using telehealth in primary care

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This interventional study compares two primary care–based telehealth strategies for adults with type 2 diabetes and at least one other chronic condition who also have a physical disability. Participants are randomized to receive either digital health coaching or remote patient monitoring through teleconsultations, with the aim of improving glycemic control and patient-reported outcomes. The trial uses real-world primary care settings to assess feasibility, effectiveness, and potential for broader implementation to underserved populations. Outcomes include changes in HbA1c and diabetes-related distress, along with measures of implementation in routine care. The goal is to identify the more effective telehealth approach to support health equity in chronic disease management.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Physical Disability
2. Diagnosed with Type 2 Diabetes
3. Hemoglobin A1c ≥7% within 3 months of screening
4. Must have at least 1 additional chronic conditions from the list below Hypertension Congestive Heart Failure Coronary Artery Disease Hyperlipidemia Stroke Arthritis Asthma Cancer Chronic Kidney Disease (Stages 1-4) COPD Osteoporosis Multiple Sclerosis Parkinsons

Exclusion Criteria:

1. Intellectual, Learning, Developmental Disabilities
2. Non-english speakers
3. Currently pregnant
4. Significant vision loss preventing use of phone/tablet for interventions
5. Received Remote Patient Monitoring or Digital Health Coaching for T2DM management within 30 days of enrollment
6. End-stage kidney disease (on dialysis)
7. Does not report having a physical disability
8. Perceived unwillingness or inability to participate

Where it's running

• UAB Highlands Hospital/Department of Family and Community Medicine
  Birmingham, Alabama, United States Recruiting

Study contacts

• Principal investigator: Tapan Mehta, PhD — University of Alabama at Birmingham
• Study coordinator: Aseel El Zein, PhD
• Email: assilelzein@uabmc.edu
• Phone: 205-201-1507

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Acute Blood Flow Restriction Walking in Type 2 Diabetes

  This study tests whether adding blood flow restriction to treadmill walking affects immune cells in adults with type 2 diabetes.

  Recruiting University of British Columbia · Kelowna, British Columbia · NCT07928531

• Continuous Glucose Monitoring in Type 2 Diabetes Not on Insulin

  This study tests whether using a continuous glucose monitoring system helps people with type 2 diabetes who aren’t using insulin to improve blood sugar control and quality of life.

  Recruiting Medical University of Bialystok · Bialystok · NCT07919236

• Differentiating heart disease in autoimmune vs. type 2 diabetes

  This study tests whether adult-onset autoimmune diabetes (AID/LADA) and type 2 diabetes (T2D) differ in how diabetic heart disease develops, using advanced heart imaging in people with AID, T2D, and healthy controls.

  Recruiting University of Roma La Sapienza · Rome, Roma · NCT07911007

• Lifestyle Metabotype Study B: Understanding Personalized Glucose Responses

  This study tests how lifestyle, metabolism, and brain energy use relate to each person’s blood sugar response after meals, across people with and without prediabetes or type 2 diabetes.

  Recruiting at 2 sites German Institute of Human Nutrition · Berlin and 1 other locations · NCT07888257

• Lifestyle Metabotype Study: How Daily Habits Shape Blood Sugar

  This observational study tests whether personal lifestyle and biological factors can predict how a person’s blood sugar responds after meals.

  Recruiting German Institute of Human Nutrition · Potsdam, Potsdam-Rehbrücke · NCT07868601

• Switching to Zenagamtide From Tirzepatide in Adults With Overweight or Obesity With or Without Type 2 Diabetes

  This study tests whether adults who are overweight or have obesity (with or without type 2 diabetes) can switch from tirzepatide to a new treatment called zenagamtide to find a tolerable dose.

  Recruiting at 2 sites Phase 1 Novo Nordisk A/S · Glendale, California and 1 other locations · NCT07868354

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.